Loading
  • Pipeline Pipeline
    • Pipeline Chart
    • uPAR-targeted radiopharmaceuticals
    • MNPR-101
      • Overview
      • Development Strategy
      • SNMMI Poster June 2024
      • EANM Presentation October 2024
    • Collaborations
      • Overview
      • Current Collaborations
    • Publications
      • MNPR-101
    • ALXN1840
      • EASL Poster May 2025
  • Investors Investors
    • Overview
    • Annual Meeting
    • News / Events
      • Press Releases
      • IR Calendar
      • In the News
      • Email Alerts
    • Company Information
      • Profile
      • Presentations
      • Our Team
      • FAQ
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Corporate Governance
      • Board of Directors
      • Board Committees
      • Governance Documents
  • Our Team Our Team
  • Careers Careers
  • Contact Us Contact Us
  • Home
  • Investors
  • News / Events
  • Press Releases
Investors

Investors

  • Overview
  • Annual Meeting
  • News / Events
    • Press Releases
    • IR Calendar
    • In the News
    • Email Alerts
  • Company Info
    • Profile
    • Presentations
    • Our Team
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Press Releases
  • IR Calendar
  • In the News
  • Email Alerts

Press Releases

Monopar Therapeutics Inc. Announces Full Exercise of Over-Allotment by Underwriters

Dec 20, 2019

Monopar Therapeutics Inc. Announces Pricing of Initial Public Offering

Dec 18, 2019

Monopar Therapeutics and the Spanish Sarcoma Group (GEIS) Team Up on Phase 2 Sarcoma Trial With Monopar's Novel Camsirubicin

Jul 2, 2019

Monopar Therapeutics, Inc. Announces Acquisition of GPX-150, a Broad Spectrum Phase II Cancer Drug Candidate, Closing on $9.7M in Financing, and Filing of Form 10 Registration Statement

Nov 14, 2017

Monopar Therapeutics Announces Partnership With Cancer Research UK And Cancer Research Technology To Develop New Oncology Compound

Jul 9, 2015

Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award

Jul 7, 2015
RSS
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • About
    • Pipeline
    • Investors
    • Our Team
    • Careers
    • Contact Us
    • Pipeline
    • Pipeline Chart
    • uPAR-targeted radiopharmaceuticals
    • MNPR-101
    • Collaborations
    • Publications
    • ALXN1840
    • Investors
    • Overview
    • Annual Meeting
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance

    Terms and Conditions of Use

    © 2025 Monopar Therapeutics Inc. All Rights Reserved.